EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

被引：0
|
作者：
Gumus, Mahmut
Geredeli, Caglayan
Ucar, Mahmut
Kaya, Serap
Demir, Hacer
Unal, Olcun Umit
Degirmenci, Mustafa
Dogu, Gamze Gokoz
Turan, Nedim
Yildirim, Nilgun
Basal, Fatma Bugdayci
Arpaci, Erkan
Karaagac, Mustafa
Harputluoglu, Hakan
Turk, Had Mehmet
Dane, Faysal
Ozkan, Metin
机构：
[1] Istanbul Medeniyet Univ Hosp, Dept Med Oncol, Istanbul, Turkey
[2] Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[3] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey
[4] Marmara Univ, Med Oncol, Istanbul, Turkey
[5] Gazi Univ, Fac Med, Med Oncol Clin, Ankara, Turkey
[6] Ataturk Training & Res Hosp, Izmir, Turkey
[7] Tepecik Educ & Res Hosp, Izmir, Turkey
[8] Pamukkale Univ, Denizli, Turkey
[9] Cumhuriyet Univ, Sch Med, Dept Med Oncol, Sivas, Turkey
[10] Ataturk Univ, Dept Med Oncol, Erzurum, Turkey
[11] Ankara Numone Training & Res Hosp, Dept Med Oncol, Ankara, Turkey
[12] Bulent Ecevit Univ, Zonguldak, Turkey
[13] Konya Necmeddin Erbakan Univ, Meram Sch Med, Diyarbakir, Turkey
[14] Inonu Univ, Dept Med Oncol, Fac Med, Malatya, Turkey
[15] Bezmialem Univ, Med Oncol, Istanbul, Turkey
[16] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15028
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Spotlight on Panitumumab in Metastatic Colorectal Cancer
    Keating, Gillian M.
    BIODRUGS, 2010, 24 (04) : 275 - 278
  • [32] Spotlight on Panitumumab in Metastatic Colorectal Cancer
    Gillian M. Keating
    BioDrugs, 2010, 24 : 275 - 278
  • [33] Panitumumab (Vectibix) for metastatic colorectal cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1259): : 35 - 36
  • [34] Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Nicola Normanno
    Sabine Tejpar
    Floriana Morgillo
    Antonella De Luca
    Eric Van Cutsem
    Fortunato Ciardiello
    Nature Reviews Clinical Oncology, 2009, 6 : 519 - 527
  • [35] Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Normanno, Nicola
    Tejpar, Sabine
    Morgillo, Floriana
    De Luca, Antonella
    Van Cutsem, Eric
    Ciardiello, Fortunato
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (09) : 519 - 527
  • [36] Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    Hecht, J. Randolph
    Patnaik, Amita
    Berlin, Jordan
    Venook, Alan
    Malik, Lmtiaz
    Tchekmedyian, Simon
    Navale, Lynn
    Amado, Rafael G.
    Meropol, Neal J.
    CANCER, 2007, 110 (05) : 980 - 988
  • [37] Panitumumab confers QoL benefits on patients with metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (3): : 123 - 124
  • [38] Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
    Parseghian, Christine
    Eluri, Madhulika
    Kopetz, Scott
    Raghav, Kanwal
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [39] Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
    Lorenzato, Annalisa
    Magri, Alessandro
    Matafora, Vittoria
    Audrito, Valentina
    Arcella, Pamela
    Lazzari, Luca
    Montone, Monica
    Lamba, Simona
    Deaglio, Silvia
    Siena, Salvatore
    Bertotti, Andrea
    Trusolino, Livio
    Bachi, Angela
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Arena, Sabrina
    CANCERS, 2020, 12 (03)
  • [40] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Chong, Curtis R.
    Jaenne, Pasi A.
    NATURE MEDICINE, 2013, 19 (11) : 1389 - 1400
12345